Tyra Biosciences doses first patient in Phase 1/2 SURF301 study of TYRA-300

Tyra Biosciences, Inc.

First patient dosed in SURF301 Phase 1/2 study of TYRA-300 for FGFR3+ advanced solid tumors.
Multi-center, open-label study to determine optimal/MTD/RP2D and evaluate antitumor activity.
Study targets both untreated and resistant FGFR3+ solid tumors; announced Nov 29, 2022.

item 8.01

Tyra Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-293899

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.